Overview of AVIM Therapy and Study Findings
Orchestra BioMed is making strides in the biomedical field with its innovative AVIM therapy. Recent clinical data published in JACC: Advances showcases how this therapy can significantly enhance cardiac function for those affected by hypertension and diastolic dysfunction, both of which are critical contributors to heart failure with preserved ejection fraction (HFpEF).
Significance of Hypertension and Diastolic Dysfunction
Hypertension commonly leads to diastolic dysfunction, particularly among older adults. This condition is often indicated in patients requiring a pacemaker. Given the increasing prevalence of these health issues, the importance of effective treatments can't be overstated.
Impact of AVIM Therapy on Clinical Measurements
The MODERATO II study has provided pivotal insights. The findings revealed that AVIM therapy contributed to a notable decrease in systolic blood pressure (SBP)—reducing office SBP by an average of 12.1±12.8 mmHg, and ambulatory SBP by 8.3±9.7 mmHg over six months. With statistical significance marked by p<0.01 when compared to baseline, these results clearly demonstrate the efficacy of AVIM therapy in managing hypertension.
Key Clinical Results from AVIM Therapy
The record from the study highlighted significant improvements in key metrics of diastolic function among patients receiving AVIM therapy. For instance, notable enhancements in e? values were recorded—rising from 5.9±2.0 to 8.8±3.4 cm/sec. Additionally, the E/A ratio improved significantly, indicating better myocardial relaxation and compliance during diastole. These findings mark a shift towards better heart performance in patients struggling with these conditions.
Expert Commentary on AVIM Therapy
Dr. Marat Fudim, an advanced heart failure cardiologist and the study's lead author, emphasized the correlation between persistent hypertension, diastolic dysfunction, and the progression to HFpEF. According to him, there are insufficient interventions currently available that target this vital pathway. The results from MODERATO II suggest that AVIM therapy is poised to fill this gap, facilitating substantial reductions in blood pressure while simultaneously enhancing ventricular compliance.
The Future of AVIM Therapy
Dr. Avi Fischer, the Senior VP of Medical Affairs and Innovation at Orchestra BioMed, asserted that treating uncontrolled hypertension, especially in pacemaker-dependent patients, is paramount. AVIM therapy offers a unique device-based solution that not only addresses hypertension but also significantly improves diastolic function. The published findings in JACC: Advances bolster the belief that AVIM therapy can deliver lasting blood pressure reductions and enhance heart rate efficiency.
Clinical Trials and Development
Currently, AVIM therapy is undergoing evaluation in the BACKBEAT global pivotal study in collaboration with Medtronic. This critical study aims to gain U.S. regulatory approval for the therapy among patients facing uncontrolled hypertension.
Orchestra BioMed’s Commitment
Orchestra BioMed’s dedication to innovation is evident through its strategic partnerships, particularly with major players like Medtronic and Terumo. Their focus is on pioneering advancements that tackle prevalent health conditions head-on, such as hypertension and atherosclerotic artery disease.
Contact and Additional Information
For further insights about Orchestra BioMed and its promising developments, individuals can visit www.orchestrabiomed.com. Those interested can follow the company’s updates on platforms such as LinkedIn.
Frequently Asked Questions
What is AVIM therapy?
AVIM therapy is an investigational treatment aimed at lowering blood pressure and improving diastolic function in patients, especially those with hypertension and indications for a pacemaker.
What were the main findings of the MODERATO II study?
The study found that AVIM therapy significantly reduced systolic blood pressure and improved echocardiographic measures of diastolic function over six months of treatment.
Who can benefit from AVIM therapy?
Patients with hypertension and diastolic dysfunction, particularly those indicated for a dual-chamber pacemaker, are the primary candidates for AVIM therapy.
What is the future of AVIM therapy?
Orchestra BioMed is focused on completing the pivotal BACKBEAT study to gain regulatory approval and expand the use of AVIM therapy in clinical settings.
How does AVIM therapy compare to other treatments?
AVIM therapy offers a unique device-based approach that targets both high blood pressure and diastolic dysfunction, marking a significant differentiation from traditional hypertension treatments.
